🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesEchocardiographic changes on GLP-1 — November 2025 Page 5

Echocardiographic changes on GLP-1 — November 2025

NeuroNate Sat, Mar 14, 2026 at 8:34 PM 29 replies 1,138 viewsPage 5 of 6
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Mar 16, 2026 at 7:20 AM#21
NurseKim_ATL said:
DoseLogDan said: ...cardiovascular risk is just another fad...

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 12 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 51" → 37" ✅ Resolved
  2. Triglycerides: 247 → 107 ✅ Resolved
  3. HDL: 35 → 59 ✅ Resolved
  4. Blood pressure: 147/93 → 120/74 ✅ Resolved
  5. Fasting glucose: 127 → 87 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

16 14NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 13 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Mar 16, 2026 at 2:11 PM#22
NurseKim_ATL said:
DoseLogDan said: ...cardiovascular risk is just another fad...

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 75 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: Mar 16, 2026 at 5:11 PM
17 15VanRx_Mike, steve_okc, dave_SLC and 14 others
Reply Quote Save Share Report
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
Mar 16, 2026 at 9:03 PM#23

One thing that is still open after NurseKim_ATL’s answer:

Was that from a primary source or from a summary of one?

Last edited: Mar 17, 2026 at 2:03 AM
18 16CanadaChris, ZaraB_AL, JakeSmashed95 and 15 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Mar 17, 2026 at 3:55 AM#24
kate.chem said:
Lp(a) and cardiovascular risk: a nuance that matters.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

19 17GraceAZ_72, carl_compliance, DanielChem_CHI and 16 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Mar 17, 2026 at 10:47 AM#25
kate.chem said:
Lp(a) and cardiovascular risk: a nuance that matters.
kate.chem said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

20 18bbq_ray_KC, oliver_london, tane_welly and 17 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register